Rankings
▼
Calendar
RNAC Q3 2025 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
RNAC
Cartesian Therapeutics, Inc.
$218M
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$452,000
+16.8% YoY
Gross Profit
-$12M
-2731.2% margin
Operating Income
-$21M
-4660.6% margin
Net Income
-$36M
-7942.9% margin
EPS (Diluted)
$-1.38
QoQ Revenue Growth
+51.7%
Cash Flow
Operating Cash Flow
-$16M
Free Cash Flow
-$17M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$373M
Total Liabilities
$409M
Stockholders' Equity
-$36M
Cash & Equivalents
$143M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$452,000
$387,000
+16.8%
Gross Profit
-$12M
$387,000
-3289.9%
Operating Income
-$21M
-$18M
-19.9%
Net Income
-$36M
-$24M
-48.5%
← FY 2025
All Quarters
Q4 2025 →